Pharma Equity Group A/S

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen Other stock markets 10:30:07 2024-04-26 am EDT			5-day change	1st Jan Change
0.251 ^DKK	-1.95%		-16.05%	-41.63%

Apr. 10	Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	CI
Apr. 05	Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	CI

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

March 22, 2024 at 04:01 am EDT

Date: 22 March 2024

Announcement of the Year No. 9

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Today, Pharma Equity Group A/S has entered into an agreement with Danske Bank in Copenhagen to be Market Maker for the company. The purpose of the Market Maker scheme is to create liquidity on Nasdaq Copenhagen in the listed share, PEG. The agreement to be a Market Maker can be summarized as follows:

Danske Bank will be Market Maker from 25 March 2024
Danske Bank commits to continuously (>85% of the trading hours of Nasdaq Copenhagen's trading system) up to:
- For the equivalent of DKK 35,000 shares in PEG
The maximum spread between the buy and sell price of the PEG share must not exceed 4%
Danske Bank's quotation is made without PEG's interference
Purchases/sales are at Danske Bank's expense and risk

Any questions regarding this announcement can be directed to the company's CEO, Thomas Kaas Selsø, by email investor@pharmaequitygroup.com.

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

Attachment

2024 03 22 - Announcement no 09 - Market Maker PEG UK

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	Apr. 09	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	Apr. 05	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	Mar. 20	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	Feb. 06	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	Jan. 24	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	Jan. 22	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	Jan. 21	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 17	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	Nov. 16	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	Nov. 16	CI
Pharma Equity Group A/S Approves Board Appointments	Nov. 02	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	23-10-31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	23-08-15	MT
Pharma Equity Group A/S Announces Board Changes	23-06-15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	23-06-14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	23-06-14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	23-03-23	CI
Blue Vision A/S will Change its Name to Pharma Equity Group A/S	23-02-14	CI
Blue Vision A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Blue Vision A/S (CPSE:BLVIS A) made an offer to acquire Reponex Pharmaceuticals A/S.	22-04-04	CI

Chart Pharma Equity Group A/S

Duration

Period

More charts

Company Profile

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

2024-05-15 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-41.63%	36.77M
INVESTOR AB	+16.54%	75.59B
KOÇ HOLDING	+53.03%	16.95B
INVESTMENT AB LATOUR	+3.20%	15.78B
AB INDUSTRIVÄRDEN	+7.21%	13.87B
L E LUNDBERGFÖRETAGEN AB	-0.77%	12.3B
HAL TRUST	+9.67%	12.04B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+6.24%	10.88B
MERITZ FINANCIAL GROUP INC.	+34.86%	10.17B
GROUPE BRUXELLES LAMBERT SA	-1.71%	9.7B